


0360
Rec'd
Self

CERTIFICATE OF HAND DELIVERY Applicant(s): EGAWA, Kohji			Docket No. 31508
Serial No. 09/819,371	Filing Date 03/28/2001	Examiner	Group Art Unit 1645
Invention: CANCER CELL-SPECIFIC HLA-F ANTIGEN AND A DIAGNOSTIC METHOD OF CANCER BY USING THEREOF			
<p>I hereby certify that this Certificate of Hand Delivery; Letter (1p); Preliminary Amendment (1p); Transmittal Letter (1p); Rule 1.821(f) Statement (1p); Sequence Listing (6pp); Copy 1 and Copy 2 CD-Rs; and return postcard are being deposited with the United States Patent and Trademark Office by hand delivering said documents to the Customer Window, 2011 South Clark Place, Crystal Plaza Two, Lobby, Room 1B03, Box Sequence, Arlington, Virginia 22202 on March 15, 2002.</p> <p><u>Theresa M. Kannokey</u> (Typed or Printed Name of person Delivering Correspondence)</p> <p><u></u> (Signature of Person Delivering Correspondence)</p>			

O I P E
MAR 15 2002
RECEIVED
TRADEMARK OF



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/819,371	03/28/2001	Kohji Egawa	31508

CONFIRMATION NO. 4334

FORMALITIES LETTER



OC000000007317661

TRADEMARK
John M. Collins
HOVEY, WILLIAMS, TIMMONS & COLLINS
Suite 400
2405 Grand Blvd.
Kansas City, MO 64108

Date Mailed: 01/16/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

EGAWA, Kohji

Serial No.: 09/819,371

Filing Date: March 28, 2001

CANCER CELL-SPECIFIC HLA-F
ANTIGEN AND A DIAGNOSTIC
METHOD OF CANCER BY USING
THEREOF



Docket No. 31508

Group Art Unit 1645

Box SEQ
Assistant Commissioner of Patents
Washington, D.C. 20231

LETTER

In response to the Notice to Comply with Requirements for Patent Applications dated January 16, 2002, Applicant hereby submits the Statement required by Rule 1.821(f), a paper copy of its Sequence Listing, two CD-Rs containing the Sequence Listing, a Transmittal Letter outlining the file contents of each CD, as well as a Preliminary Amendment amending the Specification to include a reference to the Sequence Listing.

Please charge any fee associated with this submission to Deposit Account No. 19-0522.

Respectfully submitted,

HOVEY WILLIAMS LLP

By

A handwritten signature in cursive script, appearing to read "Tracey S. Truitt".

Tracey S. Truitt, Reg. No. 43,205
2405 Grand Boulevard, Suite 400
Kansas City MO 64108
(816) 474-9050

ATTORNEY FOR APPLICANT(S)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

EGAWA, Kohji

Serial No.: 09/819,371

Filing Date: March 28, 2001

CANCER CELL-SPECIFIC HLA-F ANTIGEN
AND A DIAGNOSTIC METHOD OF CANCER
BY USING THEREOF



Docket No. 31508

Group Art Unit 1645

Box SEQ
Assistant Commissioner of Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

Transmitted herewith are two CD-Rs ("compact disks-write once") labeled and hereafter referred to as Copy 1 and Copy 2.

Copy 1 and Copy 2 each contain an identical copy of a sequence listing appendix associated with and incorporated by reference into the above-identified application. The machine format of each CD-R is IBM-PC; and the operating system compatibility is Windows 95.

Copy 1 and Copy 2 each contain identical copies of the following ASCII files:

Filename	Size (Bytes)	Date of Creation
31508.st25.txt	11 KB	03/12/2002

Respectfully submitted,

HOVEY WILLIAMS LLP

By

A handwritten signature in black ink, appearing to read "Tracey Truitt".

Tracey S. Truitt, Reg. No. 43,205
2405 Grand Boulevard, Suite 400
Kansas City MO 64108
(816) 474-9050

ATTORNEY FOR APPLICANT(S)